Epizyme (NASDAQ:EPZM) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.
A number of other research analysts also recently issued reports on the company. Zacks Investment Research downgraded Epizyme from a “hold” rating to a “sell” rating in a report on Wednesday. Oppenheimer set a $26.00 price objective on Epizyme and gave the stock a “buy” rating in a report on Tuesday, December 12th. Cann reiterated a “buy” rating and set a $26.00 price objective on shares of Epizyme in a report on Tuesday, December 12th. ValuEngine downgraded Epizyme from a “hold” rating to a “sell” rating in a report on Monday, November 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Epizyme in a report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $22.67.
Epizyme (NASDAQ:EPZM) traded up $1.20 during trading hours on Friday, hitting $14.40. The company had a trading volume of 760,151 shares, compared to its average volume of 475,712. The company has a market capitalization of $1,090.00, a P/E ratio of -6.34 and a beta of 2.00. Epizyme has a fifty-two week low of $9.30 and a fifty-two week high of $20.45.
In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total transaction of $246,600.00. Following the completion of the transaction, the insider now directly owns 23,123 shares of the company’s stock, valued at $380,142.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 25.20% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. BB&T Securities LLC acquired a new position in Epizyme during the second quarter valued at approximately $181,000. SG Americas Securities LLC lifted its position in shares of Epizyme by 83.3% in the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 6,072 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in shares of Epizyme in the second quarter valued at approximately $215,000. Fox Run Management L.L.C. acquired a new stake in shares of Epizyme in the third quarter valued at approximately $223,000. Finally, JGP Global Gestao de Recursos Ltda. acquired a new stake in shares of Epizyme in the third quarter valued at approximately $292,000. 85.28% of the stock is owned by hedge funds and other institutional investors.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.